Fig. 1.

Frameshift (FS) PCV and FAST vaccine design and peptide selection. a Schematic diagram of PCV and FAST Fs vaccine approaches. Mice were subcutaneously (s.c.) inoculated with 4 T1 tumor cells and, seven days later, sera were collected. Pre- and post-challenge sera were assayed on FSP microarrays. For PCVs, the top 10 peptides with the highest median fluorescent intensity were selected for each mouse, individual PCVs constructed and administrated to the respective mouse (n = 10). A breast cancer FAST vaccine (BC-FAST) was composed of the top 10 candidates with the highest prevalence across all 4 T1 challenged mice (n = 24). Mice (n = 10/group) were vaccinated with PCVs s.c. (opposite side of the challenge) on days 12 and 19, or with FAST vaccines on days 7 and 14. For the ICI co-treated groups, anti-PD-L1 (200 μg/dose) and anti-CTLA-4 (100 μg/dose) were administrated intraperitoneally (i.p.) on days 13, 15, 20, 22 (PCVs) and 8,15 and 22 (FAST). b Heat map of the FS peptides selected for BC-FAST and pancreatic cancer FAST (PC-FAST) vaccines. c Heat map of the FS peptides selected for PCVs